Viking Therapeutics, Inc.
HealthcareNASDAQ:VKTX · NASDAQ Capital Market
+$0.14 today
Vol 1.15M · Avg 2.23M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-56.3%
avg -73.2%
ROIC
-61.5%
avg -49.5%
ROA
-50.2%
avg -48.2%
Analysis
ROA is currently the strongest return metric at -50.2% versus its period average of -48.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Brian Lian | President, Chief Executive Officer & Director | $1.04M | — | 60 | $2.50M | 2.15% |
Marianne Mancini | Chief Operating Officer | $765,000.00 | — | 61 | $434,890.00 | 0.37% |
Gregory S. Zante | Chief Financial Officer | $738,000.00 | — | 55 | $191,371.00 | 0.16% |
Michael Morneau | Vice President of Finance & Administration | $375,333.00 | — | 61 | $116,062.00 | 0.10% |
Neil Aubuchon | Chief Commercial Officer | — | — | 55 | $4,475.00 | <0.01% |
Geoffrey E. Barker | Chief Development Officer | — | — | — | — | — |
Nils U. Olsson | Senior Vice President of Technical Operations | — | — | — | — | — |
Katherine Mercier | Vice President of Quality and Compliance | — | — | — | — | — |
Kenneth Herman | Senior Vice President of Commercial, Marketing & Sales | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$149,912.50
Sells
20
$16.97M
Net Sentiment
$16.82M
Net selling
Most Active
ZANTE GREG
6 transactions
1–10 of 21
Analysis
Insiders reported 1 buys worth $149,912.50 and 20 sells worth $16.97M over the last 12 months. That adds up to net selling of $16.82M. ZANTE GREG was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A15 analysts |
| Net Income | N/A | N/A | N/A | N/A15 analysts |
| EBIT | N/A | N/A | N/A | N/A15 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.09B
Immunovant, Inc.
NASDAQ:IMVT
$6.90B
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.64B
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
$5.12B
Akero Therapeutics, Inc.
AKRO
$4.50B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.63B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.61B
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
$3.55B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Ascentage Pharma Group International
NASDAQ:AAPG
$409.04M
Who manages VKTX?
Viking Therapeutics, Inc. (VKTX) lists 9 active executives. The top listed executive is Neil Aubuchon, Chief Commercial Officer.
Are VKTX insiders buying or selling?
Recent insider activity shows net selling of $107.22M.
Explore More
Continue the stock analysis
Jump to another research area for this company.